

Appendix 3Y

Change of Director's Interest Notice **(Amendment of notice released to the ASX 17 November 2017)**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Impression Healthcare Limited
ACN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alistair Glen BLAKE
Date of last notice	2 June 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect and Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Alistair Pty Ltd
Date of change	17 November 2017
No. of securities held prior to change	Alistair Pty Ltd (i) 15,185,841 ordinary fully paid shares (unlisted restricted) (ii) 6,902,655 Class A Performance shares (unlisted restricted) (iii) 6,902,655 Class B Performance shares (unlisted restricted) Alistair Glen Blake (i) 147,157 Fully Paid Ordinary Shares
Class	(i) Fully Paid Ordinary Shares (ii) Class A Performance shares (iii) Class B Performance shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	<p>500,000 Fully Paid Ordinary Shares indirectly in the name of Alistair Pty Ltd as part of the Company's Non-Renounceable Rights Offer to all shareholders</p> <p>500,000 Options exercisable at 4 cents expiring 30 September 2020 indirectly in the name of Alistair Pty Ltd as part of the Company's Non-Renounceable Rights Offer to all shareholders</p> <p>55,184 Fully Paid Ordinary Shares indirectly in the name of Alistair Glen Blake as part of the Company's Non-Renounceable Rights Offer to all shareholders</p> <p>55,184 Options exercisable at 4 cents expiring 30 September 2020 indirectly in the name of Alistair Glen Blake as part of the Company's Non-Renounceable Rights Offer to all shareholders</p>
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>\$11,103 for ordinary shares</p> <p>Free attaching option as part of the Non-Renounceable Rights Offer</p>
No. of securities held after change	<p>Alistair Pty Ltd</p> <ul style="list-style-type: none"> (i) 15,185,841 ordinary fully paid shares (unlisted restricted) (ii) 500,000 ordinary fully paid shares (iii) 6,902,655 Class A Performance shares (unlisted restricted) (iv) 6,902,655 Class B Performance shares (unlisted restricted) (v) 500,000 options exercisable at 4 cents expiry 30 September 2020 <p>Alistair Glen Blake</p> <ul style="list-style-type: none"> (i) 202,341 Fully Paid Ordinary Shares (ii) 55,184 options exercisable at 4 cents expiry 30 September 2020
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Shares and Options acquired as part of the Company's Non-Renounceable Rights Offer to all shareholders.

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

⁺ See chapter 19 for defined terms.